RxDoctor Payments Data

Samer Narouze, MD

Pain Medicine · Cuyahogo Falls, OHNPI 1780776351

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (39.3%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Vertex at 33.9% of the total.

$11,769in general payments, 2019–2025

Across 95 payments — averaging $123.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$4K
  • Amgen$2K
  • Boston Scientific$2K
  • Brixton Biosciences, Inc.$730
  • Abbott$567
  • Globus Medical$491
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$3,99034%
  • Speaking & faculty fees$3,13027%
  • Food & beverage$4,62539%
  • Education$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,769 in reported general payments places this provider in the 85th percentile of 245 pain medicine providers in Ohio.

See all pain medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$63,775
Medicare patients
318
Services billed
722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate13$24,873
Buprenorphine53$11,657
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen284$4,794
Lidocaine38$3,968
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen189$2,623
Gabapentin236$2,148
Pregabalin84$1,721
Oxcarbazepine25$1,042
Diclofenac Sodium27$913
Tizanidine Hcl180$841
Naloxone Hcl12$682
Baclofen74$671
Oxycodone Hcl61$605
Tramadol Hcl95$499
Duloxetine Hcl17$269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$44$24,87313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 245 pain medicine providers in Ohio.

Other pain medicine in Cuyahogo Falls

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →